<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01373086</url>
  </required_header>
  <id_info>
    <org_study_id>CLFF269X2201</org_study_id>
    <nct_id>NCT01373086</nct_id>
  </id_info>
  <brief_title>LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension</brief_title>
  <official_title>A Multi-center, Randomized, Double-blind, Placebo and Active Controlled, Parallel Group, Proof-of-concept Study to Evaluate the Efficacy and Safety of LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the efficacy and safety of LFF269 compared to placebo after treatment
      in subjects with essential hypertension.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean 24-hour systolic blood pressure (SBP) as measured by ambulatory blood pressure monitoring (ABPM) after 4 weeks treatment</measure>
    <time_frame>Baseline, week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean 24-hour diastolic blood pressure (DBP) as measured by ABPM after 4 weeks of treatment</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean 24-hour SBP and DBP as measured by ABPM after 4 weeks treatment</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients experiencing adverse events during the study as measure of safety and tolerability</measure>
    <time_frame>4 weeks</time_frame>
    <description>Adverse events will be reported as percentage of patients with total adverse events, serious adverse events and death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sitting SBP and DBP after 4 weeks treatment</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients achieving a successful BP response (&gt; placebo) and BP control (SBP &lt; 140 mmHg at trough)</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change from baseline in mean daytime and mean nighttime SBP and DBP as measured by ABPM after 4 weeks treatment</measure>
    <time_frame>Baseline, week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of LFF269: Plasma concentrations of LFF269</measure>
    <time_frame>pre dose &amp; 6 hours post study drug dose</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>LFF269 low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LFF269 low dose + Matching Placebo to Eplerenone 50mg during 4 week double blind period</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LFF269 high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LFF269 high dose + Matching Placebo to Eplerenone 50mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eplerenone 50mg twice daily + matching placebo of LFF269</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo of LFF269 high dose + Placebo of Eplerenone 50 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LFF269</intervention_name>
    <arm_group_label>LFF269 low dose</arm_group_label>
    <arm_group_label>LFF269 high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone</intervention_name>
    <arm_group_label>Eplerenone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>LFF269 low dose</arm_group_label>
    <arm_group_label>Eplerenone</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>LFF269 high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female (post-menopausal or surgically sterile).

          2. Age from 18 to 75 years inclusive.

          3. Subjects with mild-to-moderate uncomplicated essential hypertension, with (not more
             than 2 in combination) or without prior treatment.

          4. Subjects must weigh at least 50 kg to participate in the study, and must have a body
             mass index (BMI) within the range of 18 - 36 kg/m2.

        Exclusion Criteria:

          1. History or evidence of a secondary form of hypertension,

          2. History of cardiovascular disease. Type 1 or type 2 diabetes mellitus.

          3. Clinically significant valvular heart disease.

        Other protocol-defined inclusion/exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Advanced Clinical Research Institute-Phase I</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Phase I</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>333901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Phase OneÂ®,</name>
      <address>
        <city>Miramar</city>
        <state>Florida</state>
        <zip>33025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive NeuroScience</name>
      <address>
        <city>St Petersburg</city>
        <state>Florida</state>
        <zip>33716</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Atlanta</name>
      <address>
        <city>Stockbridge</city>
        <state>Georgia</state>
        <zip>30281</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage/ Prairie Fields Family Medicine, PC</name>
      <address>
        <city>Fremont</city>
        <state>Nebraska</state>
        <zip>68025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Internal Medicine Physicians</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Developmental Solutions</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68154</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Advantage/ Aloha Medical</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89183</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ICON Development Solutions,</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Clinical Development NW, Inc.</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98418</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 24, 2011</study_first_submitted>
  <study_first_submitted_qc>June 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2011</study_first_posted>
  <disposition_first_submitted>November 30, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 30, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">December 4, 2012</disposition_first_posted>
  <last_update_submitted>November 30, 2012</last_update_submitted>
  <last_update_submitted_qc>November 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hypertension,</keyword>
  <keyword>mild hypertension,</keyword>
  <keyword>moderate hypertension,</keyword>
  <keyword>high blood pressure,</keyword>
  <keyword>uncomplicated hypertension.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

